InvestorsHub Logo
Followers 1
Posts 392
Boards Moderated 0
Alias Born 03/16/2019

Re: None

Thursday, 12/19/2019 2:55:44 PM

Thursday, December 19, 2019 2:55:44 PM

Post# of 13041
as of Sept. 2019 before terminating Infusions agreements

As of September 30, 2019, the Company YTD had $157,711 cash and $1,395,860 of revenue to meets its ongoing operating expenses, and liabilities of $7,804,922 of which $5,981,119 are due within 12 months.


https://fintel.io/doc/sec/1736865/000149315219019418/form10-q.htm